Company Overview
Snapshot
Founded in May 2024 by Omar Shhady, DERMALYTE operates with 1–10 employees. The company is currently in the pre-proof-of-concept stage, advancing intellectual property protection, feasibility validation, and early experimental planning.
Business overview
DERMALYTE is an early-stage medical device venture developing a clinically oriented transdermal delivery platform. This platform is designed to functionally replace traditional intravenous (IV) infusion for administering essential minerals and electrolytes, addressing the invasiveness and delays associated with current IV methods. The core innovation lies in a system-level delivery architecture that enables controlled, clinically relevant systemic administration without venous cannulation, targeting acute care environments such as hospitals and emergency departments. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is DERMALYTE's primary focus?
- DERMALYTE is developing a smart transdermal delivery patch designed to functionally replace traditional intravenous (IV) infusion for administering essential minerals and electrolytes.
- When was DERMALYTE founded?
- DERMALYTE was founded in May 2024.
- Who is the founder of DERMALYTE?
- Omar Shhady is the founder of DERMALYTE.
- What problem does DERMALYTE aim to solve?
- DERMALYTE aims to address the limitations of current healthcare workflows where IV infusion is the standard, despite its invasiveness, delays in therapy initiation, and reliance on trained venous access.
- What is the current stage of DERMALYTE's product development?
- DERMALYTE is currently in the pre-proof-of-concept stage, focusing on intellectual property protection, feasibility validation, and early experimental planning.